• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鼻腔用皮质类固醇治疗变应性鼻炎的药理学、粒子沉积和药物给药技术。

Pharmacology, particle deposition and drug administration techniques of intranasal corticosteroids for treating allergic rhinitis.

机构信息

Department of Clinical Pharmacy and Pharmacology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.

Department PharmacoTherapy, Epidemiology and Economy, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.

出版信息

Clin Exp Allergy. 2022 Nov;52(11):1247-1263. doi: 10.1111/cea.14212. Epub 2022 Aug 23.

DOI:10.1111/cea.14212
PMID:35947495
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9804774/
Abstract

This review presents an overview of the available literature regarding intranasal corticosteroids (INCs) for the treatment of allergic rhinitis (AR). Various treatment options exist for AR including INCs, antihistamines and leucotriene antagonists. INCs are considered to be the most effective therapy for moderate-to-severe AR, as they are effective against nasal and ocular symptoms and improve quality of life. Their safety has been widely observed. INCs are effective and safe for short-term use. Local adverse events are observed but generally well-tolerated. The occurrence of (serious) systemic adverse events is unlikely but cannot be ruled out. There is a lack of long-term safety data. INC may cause serious eye complications. The risk of INCs on the hypothalamic-pituitary-adrenal axis, on bone mineral density reduction or osteoporosis and on growth in children, should be considered during treatment. Pharmacological characteristics of INCs (e.g. the mode of action and pharmacokinetics) are well known and described. We sought to gain insight into whether specific properties affect the efficacy and safety of INCs, including nasal particle deposition, which the administration technique affects. However, advances are lacking regarding the improved understanding of the effect of particle deposition on efficacy and safety and the effect of the administration technique. This review emphasizes the gaps in knowledge regarding this subject. Advances in research and health care are necessary to improve care for patients with AR.

摘要

这篇综述介绍了鼻腔内皮质类固醇(INCs)治疗过敏性鼻炎(AR)的现有文献概述。AR 的各种治疗选择包括 INCs、抗组胺药和白三烯拮抗剂。INCs 被认为是中重度 AR 的最有效治疗方法,因为它们对鼻腔和眼部症状均有效,并能改善生活质量。其安全性已得到广泛观察。INCs 短期使用有效且安全。局部不良事件虽有发生,但通常可耐受。(严重)全身性不良事件的发生不太可能,但不能排除。缺乏长期安全性数据。INC 可能引起严重眼部并发症。在治疗过程中应考虑 INCs 对下丘脑-垂体-肾上腺轴、骨矿物质密度降低或骨质疏松症以及儿童生长的影响。INCs 的药理学特性(如作用模式和药代动力学)是众所周知的,并已作描述。我们试图深入了解是否特定特性会影响 INCs 的疗效和安全性,包括鼻腔颗粒沉积,而这会受给药技术影响。然而,在改善对颗粒沉积对疗效和安全性的影响以及给药技术的影响的理解方面,进展仍有限。这篇综述强调了这一主题的知识空白。需要在研究和医疗保健方面取得进展,以改善 AR 患者的护理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72a1/9804774/0c68a49ffc0b/CEA-52-1247-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72a1/9804774/fe8728aa7494/CEA-52-1247-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72a1/9804774/8425408405f0/CEA-52-1247-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72a1/9804774/0c68a49ffc0b/CEA-52-1247-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72a1/9804774/fe8728aa7494/CEA-52-1247-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72a1/9804774/8425408405f0/CEA-52-1247-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72a1/9804774/0c68a49ffc0b/CEA-52-1247-g003.jpg

相似文献

1
Pharmacology, particle deposition and drug administration techniques of intranasal corticosteroids for treating allergic rhinitis.鼻腔用皮质类固醇治疗变应性鼻炎的药理学、粒子沉积和药物给药技术。
Clin Exp Allergy. 2022 Nov;52(11):1247-1263. doi: 10.1111/cea.14212. Epub 2022 Aug 23.
2
Combined medical therapy in the treatment of allergic rhinitis: Systematic review and meta-analyses.联合药物治疗变应性鼻炎:系统评价与荟萃分析
Int Forum Allergy Rhinol. 2022 Dec;12(12):1480-1502. doi: 10.1002/alr.23015. Epub 2022 May 8.
3
Effects of H1 antihistamine addition to intranasal corticosteroid for allergic rhinitis: a systematic review and meta-analysis.抗组胺药 H1 联合鼻内皮质类固醇治疗变应性鼻炎的效果:系统评价和荟萃分析。
Int Forum Allergy Rhinol. 2018 Oct;8(10):1083-1092. doi: 10.1002/alr.22166. Epub 2018 Jun 19.
4
Intranasal antihistamine is superior to oral H antihistamine as an add-on therapy to intranasal corticosteroid for treating allergic rhinitis.鼻腔抗组胺药作为一种附加疗法,优于口服 H 抗组胺药,用于治疗变应性鼻炎的鼻腔皮质类固醇。
Ann Allergy Asthma Immunol. 2020 Nov;125(5):589-596.e3. doi: 10.1016/j.anai.2020.06.038. Epub 2020 Jul 7.
5
As-needed intranasal corticosteroid spray for allergic rhinitis: a systematic review and meta-analysis.按需鼻内皮质类固醇喷雾治疗变应性鼻炎:系统评价和荟萃分析。
Rhinology. 2022 Aug 1;60(4):242-251. doi: 10.4193/Rhin21.355.
6
Intranasal corticosteroids reduced acute rhinosinusitis in children with allergic rhinitis: A nested case-control study.鼻内使用皮质类固醇可降低变应性鼻炎患儿的急性鼻-鼻窦炎:一项巢式病例对照研究。
J Microbiol Immunol Infect. 2024 Feb;57(1):175-183. doi: 10.1016/j.jmii.2023.11.005. Epub 2023 Dec 4.
7
Impact of intranasal corticosteroids on asthma outcomes in allergic rhinitis: a meta-analysis.鼻内皮质类固醇对变应性鼻炎哮喘结局的影响:荟萃分析。
Allergy. 2013;68(5):569-79. doi: 10.1111/all.12124.
8
Effect of Medical Therapy in Allergic Rhinitis: A Systematic Review and Meta-Analysis.变应性鼻炎的药物治疗效果:系统评价和荟萃分析。
Am J Rhinol Allergy. 2022 Mar;36(2):269-280. doi: 10.1177/19458924211041438. Epub 2021 Sep 21.
9
Effects of double-dose intranasal corticosteroid for allergic rhinitis: a systematic review and meta-analysis.双剂量鼻内皮质类固醇治疗变应性鼻炎的效果:系统评价和荟萃分析。
Int Forum Allergy Rhinol. 2019 Jan;9(1):72-78. doi: 10.1002/alr.22204. Epub 2018 Sep 4.
10
Leukotriene receptor antagonist addition to intranasal steroid: systematic review and meta-analysis.白三烯受体拮抗剂联合鼻内类固醇:系统评价和荟萃分析。
Rhinology. 2021 Feb 1;59(1):2-9. doi: 10.4193/Rhin20.126.

引用本文的文献

1
Acoustic therapy for allergic rhinitis and chronic rhinosinusitis: modulating microbiome, immunity and well-being.变应性鼻炎和慢性鼻-鼻窦炎的声学疗法:调节微生物群、免疫和健康状况
Front Allergy. 2025 Aug 25;6:1649031. doi: 10.3389/falgy.2025.1649031. eCollection 2025.
2
A multidisciplinary Delphi consensus on budesonide aqueous nasal spray in managing upper respiratory diseases.布地奈德水性鼻喷雾剂治疗上呼吸道疾病的多学科德尔菲共识
Multidiscip Respir Med. 2025 Mar 3;20(1):1015. doi: 10.5826/mrm.2025.1015.
3
Orthonasal and retronasal olfactory function in patients with chronic rhinosinusitis without nasal polyps undergoing endoscopic sinonasal surgery.

本文引用的文献

1
As-needed intranasal corticosteroid spray for allergic rhinitis: a systematic review and meta-analysis.按需鼻内皮质类固醇喷雾治疗变应性鼻炎:系统评价和荟萃分析。
Rhinology. 2022 Aug 1;60(4):242-251. doi: 10.4193/Rhin21.355.
2
Intranasal Corticosteroids: Topical Potency, Systemic Activity and Therapeutic Index.鼻内用皮质类固醇:局部效力、全身活性及治疗指数。
J Asthma Allergy. 2021 Sep 8;14:1093-1104. doi: 10.2147/JAA.S321332. eCollection 2021.
3
Hypothalamic-pituitary-adrenal axis suppression and intranasal corticosteroid use: A systematic review and meta-analysis.
接受鼻内镜鼻窦手术的无鼻息肉慢性鼻窦炎患者的经鼻和鼻后嗅觉功能
Int Forum Allergy Rhinol. 2025 Feb;15(2):157-165. doi: 10.1002/alr.23467. Epub 2024 Oct 10.
4
Inter-societal Delphi Consensus on the topical nasal treatments in Italy.意大利关于局部鼻腔治疗的跨学会德尔菲共识。
Multidiscip Respir Med. 2024 Sep 4;19(1):991. doi: 10.5826/mrm.2024.991.
5
Management of Allergic Rhinitis in the United Arab Emirates: Expert Consensus Recommendations on Allergen Immunotherapy.阿拉伯联合酋长国变应性鼻炎的管理:变应原免疫治疗专家共识建议
Cureus. 2024 Jul 24;16(7):e65260. doi: 10.7759/cureus.65260. eCollection 2024 Jul.
6
An Overview of Adherence-What It Is and Why It Is Important.依从性概述——它是什么以及为何重要。
J Allergy Clin Immunol Pract. 2024 Dec;12(12):3180-3188. doi: 10.1016/j.jaip.2024.07.018. Epub 2024 Jul 27.
7
Correlation among post-surgery recurrence of CRSwNP and TCM syndromes and tissue inflammatory cell infiltration type: a study protocol.术后慢性鼻-鼻窦炎伴鼻息肉(CRSwNP)复发与中医证候及组织炎症细胞浸润类型的相关性研究:研究方案。
Syst Rev. 2024 May 30;13(1):145. doi: 10.1186/s13643-024-02562-9.
8
The Efficacy of Elonide Nasal Corticosteroids in Managing Allergic Rhinitis: A Randomized, Double-Blinded Trial.依洛奈德鼻用皮质类固醇治疗变应性鼻炎的疗效:一项随机双盲试验
J Clin Med. 2024 Mar 25;13(7):1883. doi: 10.3390/jcm13071883.
9
Pathogenesis of allergic diseases and implications for therapeutic interventions.过敏性疾病的发病机制及治疗干预的意义。
Signal Transduct Target Ther. 2023 Mar 24;8(1):138. doi: 10.1038/s41392-023-01344-4.
下丘脑-垂体-肾上腺轴抑制与鼻内皮质类固醇使用:系统评价和荟萃分析。
Int Forum Allergy Rhinol. 2022 Jan;12(1):11-27. doi: 10.1002/alr.22863. Epub 2021 Jul 14.
4
The Quality of Instructional YouTube Videos for the Administration of Intranasal Spray: Observational Study.用于鼻内喷雾给药的YouTube教学视频质量:观察性研究。
JMIR Med Educ. 2020 Dec 30;6(2):e23668. doi: 10.2196/23668.
5
Observational study of administering intranasal steroid sprays by healthcare workers.医护人员经鼻给予类固醇喷雾的观察性研究。
BMJ Open. 2020 Aug 30;10(8):e037660. doi: 10.1136/bmjopen-2020-037660.
6
Intranasal Corticosteroid Therapy: Systematic Review and Meta-analysis of Reported Safety and Adverse Effects in Children.鼻腔皮质类固醇治疗:儿童报告的安全性和不良反应的系统评价和荟萃分析。
Otolaryngol Head Neck Surg. 2020 Dec;163(6):1087-1096. doi: 10.1177/0194599820931454. Epub 2020 Jul 14.
7
Intranasal Corticosteroid Therapy: Systematic Review and Meta-analysis of Reported Safety and Adverse Effects in Adults.鼻内皮质类固醇治疗:成人报告的安全性和不良反应的系统评价和荟萃分析。
Otolaryngol Head Neck Surg. 2020 Dec;163(6):1097-1108. doi: 10.1177/0194599820931455. Epub 2020 Jun 16.
8
Efficacy of fluticasone exhalation delivery system in the management of chronic rhinosinusitis: what is the evidence?氟替卡松吸入给药系统治疗慢性鼻-鼻窦炎的疗效:有何证据?
Int Forum Allergy Rhinol. 2019 May;9(S1):S16-S21. doi: 10.1002/alr.22340.
9
Modulation of Allergic Inflammation in the Nasal Mucosa of Allergic Rhinitis Sufferers With Topical Pharmaceutical Agents.局部用药对变应性鼻炎患者鼻黏膜变应性炎症的调节作用
Front Pharmacol. 2019 Mar 29;10:294. doi: 10.3389/fphar.2019.00294. eCollection 2019.
10
Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study.移动技术为过敏性鼻炎的控制和治疗提供了新的见解:MASK 研究。
J Allergy Clin Immunol. 2019 Jul;144(1):135-143.e6. doi: 10.1016/j.jaci.2019.01.053. Epub 2019 Apr 3.